Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Mallinckrodt’s Generics Bounce Back Ahead Of Spin-Off

Executive Summary

Mallinckrodt’s Specialty Generics business returned to growth ahead of a planned spin-off into a separate company by the end of 2019.

You may also be interested in...



Mallinckrodt Restructures Its Spinoff And Completes Management Team

Mallinckrodt has altered the composition of the Specialty Generics business that it plans to spin off by the end of this year, removing its Amitiza brand. The firm says it now has a “full management team in place” for the Specialty Generics unit after naming Eric Slusser as chief financial officer, to serve under president and CEO Matthew Harbaugh.

Top US Court Lifts Discovery Stay On Price-Fixing

The US Supreme Court has lifted a stay on document discovery in a multi-state lawsuit in which dozens of generics companies – including Teva, Mylan and Pfizer – are accused of price fixing. The ruling will allow a swathe of documents to be released in what Connecticut’s attorney general has said is potentially “the largest cartel case” in US history.

FDA Approves First Generic Of Daraprim

Daraprim, which saw its price jacked up by 4,000% by former drug company executive Martin Shkreli, now has a competitor with the US Food and Drug Administration’s approval of the first generic version of the nearly seven-decade-old drug used to treat a life-threatening parasitic infection known as toxoplasmosis.

Topics

UsernamePublicRestriction

Register

GB140329

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel